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Objectives The study investigated whether the number of participants enrolled per site in an acute heart failure trial is asso-
ciated with participant characteristics and outcomes.
Background Whether and how site enrollment volume affects clinical trials is not known.
Methods A total of 4,133 participants enrolled among 359 sites were grouped on the basis of total enrollment into 1 to
10, 11 to 30, and 30 participants per site and were compared for outcomes (cardiovascular mortality or heart
failure hospitalization).
Results Per-site enrollment ranged from 0 to 75 (median 6; 77 sites had no enrollment). Regional differences in enrollment were
noted between North and South America, and Western and Eastern Europe (p 0.001). Participants from sites with fewer
enrollments were more likely to be older and male, have lower ejection fraction and blood pressure as well as worse comor-
bidity and laboratory profile, and were less likely to be on angiotensin-converting enzyme inhibitors or aldosterone antago-
nists. During a median follow-up of 9.9 months, 1,700 (41%) participants had an outcome event. Compared to event rate
at sites with30 participants (32%), those with 1 to 10 (51%, hazard ratio [HR]: 1.77, 95% confidence interval [CI]: 1.56 to
2.02) and 11 to 30 (42%, HR: 1.44, 95% CI: 1.28 to 1.62) participants per site groups had worse outcomes. This relation-
ship was comparable across regions (p 0.43). After adjustment for risk factors, participants enrolled at sites with fewer
enrollees were at higher risk for adverse outcomes (HR: 1.26, 95% CI: 1.08 to 1.46 for 1 to 10; HR: 1.22, 95% CI: 1.07 to
1.38 for 11 to 30 vs.30 participant sites). Higher proportion of participants from site with30 participants completed
the protocol (45.5% for10, 61.7% for 11 to 30, and 68.4% for sites enrolling30 participants; p 0.001).
Conclusions Baseline characteristics, protocol completion, and outcomes differed significantly among higher versus lower
enrolling sites. These data imply that the number of participant enrolled per site may influence trials beyond
logistics. (J Am Coll Cardiol 2013;61:571–9) © 2013 by the American College of Cardiology Foundation
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Site Enrollment and Trial Outcomes February 5, 2013:571–9Heart failure (HF) remains a
major global health concern (1).
The overall prevalence of HF
and the number of hospitaliza-
tions for acute heart failure
(AHF) are high, and outcomes
for these patients remain poor
(1–3). Although many therapies
have been evaluated in the last
decade, none of them reduced
mortality or readmission rates among AHF patients (4,5).
The reasons behind this are complex including issues related
to the therapies studied and trial conduct (6). AHF patients
constitute a heterogeneous group and patient characteristics
affect outcomes. Moreover, important differences between
continents, and regions within continents, in HF etiology,
severity, and management exist, which affect patient out-
comes as well (7–10).
See page 580
Recently, attention has been focused on the difficulties of
enrolling participants in clinical trials in the United States
(11). In order to enroll the required number of participants,
it is increasingly common for trials to have several hundred
sites in operation. The performance and the number of
participants enrolled by these sites vary widely. In a clinical
trial, slower enrollment rate affects the duration of the trial,
however the participants are expected to be clinically ho-
mogenous due to the pre-specified strict inclusion and
exclusion criteria. Therefore the overall enrollment by sites
may not affect outcomes of the trial besides costs and
logistics. Conversely, if outcomes of participants from high
versus low enrollment sites are different, this may have
significant implications for trial design and conduct. To assess
whether the site enrollment affects outcomes, we performed a
post hoc analysis of the data from the EVEREST (Efficacy of
Vasopressin Antagonism in Heart Failure: Outcome Study
with Tolvaptan) trial.
Methods
Study population. The design of the EVEREST trial has
been described previously (3,12,13). Briefly, EVEREST
was a prospective, international, randomized, double blind,
placebo-controlled program that examined the short- and
tion Medical, Inc., Johnson & Johnson, Medtronic, Merck, Novartis Pharma AG,
Ono Pharmaceuticals USA, Otsuka Pharmaceuticals, Palatin Technologies, PeriCor
Therapeutics, Protein Design Laboratories, Sanofi-Aventis, Sigma Tau, Solvay
Pharmaceuticals, Sticares InterACT, Takeda Pharmaceuticals North America, Inc.,
and Trevena Therapeutics; and has received support from Bayer Schering Pharma
AG, DebioPharm S.A., Medtronic, Novartis Pharma AG, Otsuka Pharmaceuticals,
Sigma Tau, Solvay Pharmaceuticals, Sticares InterACT, and Takeda Pharmaceuticals
North America, Inc. All other authors have reported that they have no relationships
relevant to the contents of this paper to disclose.
Abbreviations
and Acronyms
ACE  angiotensin-
converting enzyme
AHF  acute heart failure
CI  confidence interval
HF  heart failure
HR  hazard ration
Manuscript received August 2, 2012; revised manuscript received September 21,
2012, accepted October 9, 2012.long-term efficacy and safety of tolvaptan added to optimal
medical therapy in participants hospitalized for worsening
HF. The EVEREST program included 2 identical short-
term clinical status trials during hospitalization (trials A and
B) embedded within the long-term post-discharge outcome
study that combined all participants. Adults 18 years of
age with left ventricular ejection fraction 40% who were
hospitalized primarily for worsening HF and with 2 or more
signs or symptoms of fluid overload (i.e., dyspnea, pitting
edema, or jugular venous distension) were randomized within
48 h of admission to oral tolvaptan (30 mg/day) or matching
placebo in addition to conventional therapy. Exclusion criteria
included cardiac surgery within 60 days of enrollment, cardiac
mechanical support, biventricular pacemaker placement within
60 days, expected survival of 6 months, acute myocardial
infarction at the time of hospitalization, hemodynamically
significant uncorrected valvular disease, end-stage HF, dialysis,
systolic blood pressure 90 mm Hg, serum creatinine 3.5
g/dl, serum potassium 5.5 mEq/l, and hemoglobin 9
/dl. Background therapy was at the discretion of the treating
hysician, but recommendations for guideline-based therapy
ere included in the protocol.
linical trial sites. In the EVEREST trial, overall 4,133
articipants were randomized from 359 sites in 20 countries
cross North America, South America, and Europe between
ctober 7, 2003, and February 3, 2006. Countries were
rouped as follows: North America (United States and
anada), South America (Argentina and Brazil), Western
urope (Italy, Belgium, Norway, Netherlands, Germany,
pain, France, United Kingdom, Sweden, and Switzerland),
nd Eastern Europe (Poland, Romania, Czech Republic,
ussia, Bulgaria, and Lithuania).
tudy groups. The participants were divided into the
ollowing groups on the basis of overall participants enrolled
y an individual site into those sites that enrolled 1 to 10, 11
o 30, and 30 participants. This grouping was virtually
dentical to sample tertiles on the basis of total numbers of
articipants enrolled within these sites (1 to 11, 12 to 30,
nd 30) and was selected for ease of communication.
utcomes for patients within these 3 individual groups were
omogeneous and further subdivision did not improve
verall model fit to the data. Hence these larger groups were
sed for all further analysis and reporting of the data.
utcomes events. For this analysis the primary outcome
as defined as a composite of cardiovascular death or HF
ospitalization, 1 of the 2 coprimary endpoints in EVEREST.
ll-cause mortality, the other coprimary endpoint in EVEREST,
as also compared among the 3 groups. Multiple other clinical
utcomes were also assessed in secondary analysis including
odes of death, other cardiovascular outcomes, and hospi-
alizations. An independent event committee adjudicated
he mode of death and the cause of hospitalizations for all
articipants. An independent and blinded adjudication
ommittee determined the cause of all hospitalizations and
eaths during follow-up. Rehospitalization was defined as a
onelective hospital admission for medical therapy with a
s
i
i
d
u
s
s
d
k
s
S
r
w
a
d
a
a
d
H
i
t
p
p
f
t
a
s
c
b
m
r
u
i
a
h
p
c
f
v
a
i
m
R
S
t
e
p
(
p
e
p
1
t
R
m
T
p
2
n
1
t
e
3
p
W
p
a
S
s
A
5
E

P
p
r
b
m
573JACC Vol. 61, No. 5, 2013 Butler et al.
February 5, 2013:571–9 Site Enrollment and Trial Outcomesduration that extended over a change in calendar date. HF
hospitalization was defined as hospitalization that included
ubstantive worsening of HF symptoms and/or signs resulting
n augmentation of oral medications or new administration of
ntravenous HF therapies including ultrafiltration. Mode of
eath was adjudicated as cardiovascular, noncardiovascular, or
nknown. Cardiovascular deaths were further classified as
udden cardiac death, HF death, acute myocardial infarction,
troke, or other. Noncardiovascular death was defined as a
eath due to a specific noncardiovascular event, while un-
nown death was defined as a death for which no information
urrounding the event was available.
tatistical analysis. Demographics; physical and laboratory
findings; medical history; and medical, surgical, and device
therapies were compared among the 3 groups using the
analysis of variance for parametric, and Kruskal-Wallis test
for nonparametric variables. The Pearson chi-square test
was used for categorical variables. Continuous variables are
reported as either mean  SD or median (interquartile
ange [i.e., 25th percentile to 75th percentile]) in cases
here the distribution was not normal. Categorical variables
re reported as count and percentage. For analysis of QRS
uration, this interval was not reported in 142 participants,
nd 1,029 participants were excluded due to the presence of
pacemaker and/or implantable cardioverter-defibrillator.
Unadjusted Kaplan-Meier estimates of the rates of car-
iovascular death and HF hospitalization were calculated.
azard ratios (HR) and corresponding 95% confidence
ntervals (CI) for the primary endpoint and all-cause mor-
ality were calculated relative to sites that enrolled 30
articipants over the entire follow-up period using Cox
roportional hazards model with and without adjustment
or other baseline covariates. Confounders were adjusted on
he basis of clinical relevance and included region, study arm
ssignment, age, gender, ejection fraction, QRS duration,
ystolic blood pressure, heart rate, New York Heart Asso-
iation functional class, revascularization history, atrial fi-
rillation or flutter on baseline electrocardiogram, diabetes,
ellitus, chronic renal disease, implanted defibrillator, se-
um sodium and blood urea nitrogen concentrations, natri-
retic peptide levels, and randomization use of ACE inhib-
tors or angiotensin receptor blockers, beta-blockers,
ldosterone antagonists, and inotropes. Proportionality of
azards through time was assessed using empirical score
rocess. The sponsor performed database management ac-
ording to a pre-specified plan and the analysis was per-
ormed at the Northwestern University using SAS software,
ersion 9.3 (SAS Institute Inc., Cary, North Carolina). The
uthors had full access to the data and take responsibility for
ts integrity, and had complete control and authority over
anuscript preparation and the decision to publish.
esults
ite and participant distribution. Overall, 436 sites par-
icipated in the EVEREST trial. Of these, 77 sites did notnroll any patients. The remaining 359 sites enrolled 4,133
articipants. The enrollment per site ranged from 0 to 75
median 6) participants. Of the sites that enrolled partici-
ants, 224 (62%) sites enrolled 10, 105 (29%) sites
nrolled 11 to 30, and 30 (9%) sites enrolled 30 partici-
ants. These represented 1,052 (26%), 1,792 (43%), and
,289 (31%) participants enrolled among sites with 10, 11
o 30, and 30 participants enrolled by sites.
egional differences. Significant differences in site enroll-
ent were observed among the 4 regions studied (Fig. 1).
he highest proportion of sites that did not enroll any
articipants was observed in Western Europe (22 of 100,
2%) and North America (46 of 220, 20.9%), whereas fewer
onenrolling sites were from South America (5 of 40,
2.5%) and Eastern Europe (3 of 77, 3.9%). Of the 359 sites
hat did enroll, 173 (48%) sites were in North America and
nrolled 1,251 participants (median, 7 participants per site);
5 (10%) sites were in South America and enrolled 699
articipants (20 participants per site); 77 (21%) sites were in
estern Europe and enrolled 564 participants (7 partici-
ants per site); and 74 (21%) sites were in Eastern Europe
nd enrolled 1,619 participants (22 participants per site).
ignificant regional differences were noted in the percent of
ites within each enrollment number grouping (North
merica 75.1%, 23.1%, 1.8%; South America 25.7%,
4.3%, 20.0%; Western Europe 77.9%, 20.8%, 1.3%; and
astern Europe 23.0%, 50.0%, 27% for 10, 11 to 30, and
30 participants enrolled per site, respectively; p  0.001).
articipant characteristics. Table 1 illustrates the baseline
articipant characteristics and Table 2 shows medication at
andomization and discharge, stratified into groups on the
asis of enrollment. Participants at sites with high enroll-
ent had an overall lower risk profile for multiple clinical
Figure 1 Regional Variation in Enrollment
In general, the United States and Western Europe had more sites with fewer
enrollment, whereas the opposite was observed in South America and Eastern
Europe.
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Site Enrollment and Trial Outcomes February 5, 2013:571–9characteristics. Sites that enrolled 30 participants tended
to enroll younger participants who were more likely to be
female and white, had higher left ventricular ejection
fraction and systolic blood pressure, and shorter QRS
duration. They had less diabetes mellitus, chronic kidney
disease, chronic lung disease, and ischemic heart disease, and
underwent less coronary revascularization procedures as com-
pared with participants enrolled in sites with 10 enrollees.
Similarly, participants enrolled at higher enrolling sites had
Baseline Demographic and Clinical CharacteristicsTable 1 Baseline Demographic and Clinical Characteristics
n
Variable 1–10 11–30 >30
Demographics
Total enrolled 1,052 1,792 1,289
Age, yrs 1,052 1,792 1,289
Male 1,052 1,792 1,289
Race
White
Black
Other
Clinical characteristics
Ejection fraction, % 1,050 1,791 1,289
QRS duration, ms 986 1,707 1,244
Weight, kg 1,038 1,780 1,280
Dyspnea 1,016 1,750 1,277
Jugular venous distension 1,001 1,739 1,274
Rales 1,014 1,756 1,278
Edema 1,016 1,756 1,278
Systolic blood pressure, mm Hg 1,032 1,778 1,281
Diastolic blood pressure, mm Hg 1,031 1,778 1,281
Heart rate, beats/min 1,032 1,779 1,281
New York Heart Association functional
class IV symptoms
1,049 1,788 1,289
Comorbidity burden
Previous heart failure hospitalization 1,048 1,784 1,281
Coronary artery disease 1,050 1,789 1,289
Myocardial infarction 1,049 1,791 1,288
Hypertension 1,051 1,791 1,289
Dyslipidemia 1,051 1,790 1,271
Peripheral vascular disease 1,049 1,788 1,289
Coronary bypass surgery 1,051 1,791 1,289
Percutaneous coronary intervention 1,050 1,791 1,289
Defibrillator 1,051 1,791 1,289
Pacemaker 1,051 1,791 1,289
Diabetes 1,051 1,791 1,289
Chronic renal disease 1,051 1,790 1,289
Chronic lung disease 1,051 1,791 1,289
Laboratory profile
Serum sodium, mEq/l 971 1,716 1,263
Serum creatinine, mg/dl 973 1,721 1,265
Blood urea nitrogen, mg/dl 974 1,721 1,265
White blood count per mm3 895 1,619 1,209
B-type natriuretic peptide, pg/ml 652 1,289 1,000
N-terminal pro B-type natriuretic
peptide, pg/ml
471 610 369 5
Values are median (interquartile range), mean  SD, or n (%).lower blood urea nitrogen, white blood cell count, and natri-uretic peptide levels at baseline. Participants at sites with 30
participants had more dyspnea, rales, edema, and New York
Heart Association functional class IV symptoms but less
jugular venous distension and lower natriuretic peptide levels.
Similar differences were noted in therapy at random-
ization with participants enrolled from sites with 30
enrollees more likely to be on ACE inhibitors or angio-
tensin receptor blockers and aldosterone antagonists
therapy and less likely to be on inotropes or had im-
Enrollment Group
1–10 11–30 >30 p Value
7 (4–8) 19 (14–24) 44 (40–50)
.3 11.8 64.8 11.9 65 11.6 0.001
95 (75.6) 1,355 (75.6) 925 (71.8) 0.032
75 (83.3) 1,489 (83.1) 1,169 (90.7) 0.001
27 (12.1) 141 (7.9) 42 (3.3)
49 (4.7) 162 (9.0) 78 (6.1)
6.2 8.2 26.9 8.2 29.3 7.4 0.001
0.6 35.5 128.1 35.7 122.4 34.4 0.001
.3 19.8 84.4 18.8 79.9 17.7 0.001
84 (87.0) 1,590 (90.9) 1,205 (94.4) 0.001
93 (29.3) 512 (29.4) 277 (21.7) 0.001
96 (78.5) 1,434 (81.7) 1,065 (83.3) 0.012
63 (75.1) 1,415 (80.6) 1,064 (83.3) 0.001
8.3 19.9 120.1 19.5 122.7 19.4 0.001
.5 12.3 73.3 12.8 74.3 12.5 0.001
.1 15.3 80.2 15.7 80.8 15.8 0.001
73 (35.6) 636 (35.6) 613 (47.6) 0.001
38 (80) 1,435 (80.4) 977 (76.3) 0.014
85 (74.8) 1,223 (68.4) 903 (70.1) 0.001
76 (54.9) 877 (49) 634 (49.2) 0.005
34 (69.8) 1,290 (72) 908 (70.4) 0.407
40 (60.9) 900 (50.3) 463 (36.4) 0.001
44 (23.3) 377 (21.1) 245 (19.0) 0.042
38 (32.2) 368 (20.5) 156 (12.1) 0.001
96 (28.2) 304 (17) 138 (10.7) 0.001
39 (22.7) 249 (13.9) 112 (8.7) 0.001
59 (24.6) 308 (17.2) 148 (11.5) 0.001
94 (47.0) 716 (40.0) 388 (30.1) 0.001
39 (41.8) 476 (26.6) 192 (14.9) 0.001
58 (15.0) 168 (9.4) 90 (7.0) 0.001
9.4 4.7 139.7 4.7 139.7 4.5 0.119
.5 0.5 1.4 0.5 1.3 0.6 0.001
.4 20.1 29.2 14.7 27.4 14.2 0.001
.7 2.7 7.6 2.6 7.4 2.7 0.001
(424–1,866) 731 (316–1,516) 529 (207–1,193) 0.001
2,653–11,332) 4,607 (2,179–9,642) 3,592 (1,599–7,429) 0.00168
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February 5, 2013:571–9 Site Enrollment and Trial Outcomespants enrolled at centers with 10 participants were more
likely to be on beta-blockers.
Early withdrawal. Of the 4,133 participants randomized,
2,467 (59.7%) completed the protocol. Of the rest, 761
(18.4%) and 252 (6.1%) were early withdrawals from the
protocol due to death or adverse events. The other 653
(15.8%) of the participants did not complete the protocol
for reasons other than death or adverse event. The reasons
for these early withdrawals are listed in Table 3; they were
all numerically lower among sites with higher enrollment.
Both adverse events and other reasons for early treatment
Medication Profile at Randomization and at DiscTable 2 Medication Profile at Randomizatio
Variable 1–1
Medications at randomization
Angiotensin-converting enzyme inhibitor/
angiotensin receptor blocker
833 (
Aldosterone antagonists 434 (
Beta-blockers 789 (
Calcium-channel blockers 101 (
Digoxin 419 (
Diuretics 1,013 (
Nitrates 387 (
Lipid-lowering agents 522 (
Antiarrhythmic agents 236 (
Inotropes 68 (
Medications at discharge
Angiotensin-converting enzyme inhibitor/
angiotensin receptor blocker
835 (
Aldosterone antagonists 520 (
Beta-blockers 791 (
Calcium-channel blockers 83 (
Digoxin 442 (
Diuretics 958 (
Nitrates 321 (
Lipid lowering agents 498 (
Antiarrhythmic agents 237 (
Inotropes 22 (
Values are n (%).
Reasons for Early Discontinuation of Study TreaTable 3 Reasons for Early Discontinuation o
Study Completion Status 1–10
Randomized 1,052
Completed protocol 479 (45.5)
Early treatment termination
Death 202 (19.2)
Adverse event 124 (11.8)
Other reason 247 (23.5)
Lost to follow-up 15 (1.4)
Met withdrawal criteria* 3 (0.3)
Investigator withdrew participant 65 (6.2)
Participant withdrew consent 160 (15.2)
Protocol deviation 4 (0.4)Values are n (%). *Missed study drug for 21 consecutive days.termination were less common, and completion of protocol
more common, among sites with 30 enrolled participants
(all p  0.001).
Outcomes. During a median follow-up of 9.9 months,
1,700 (41%) participants had an event. The overall cardio-
vascular death or HF hospitalization event rate was lowest
among participants at highest enrolling sites (event rate
51%, 42%, and 32% for10, 11 to 30, and30 participants
per site enrolled, respectively; p  0.001) (Fig. 2). Com-
pared to participants enrolled at sites with 30 enrollees,
10 (HR: 1.77, 95% CI: 1.56 to 2.02) and 11 to 30 (HR:
eat Discharge
Site Enrollment Group
p Value11–30 >30
1,520 (84.9) 1,126 (87.4) 0.001
990 (55.3) 814 (63.1) 0.001
1,261 (70.4) 853 (66.2) 0.001
211 (11.8) 128 (9.9) 0.12
854 (47.7) 717 (55.6) 0.001
1,737 (97) 1,252 (97.1) 0.64
726 (40.5) 480 (37.2) 0.07
668 (37.3) 324 (25.1) 0.001
299 (16.7) 201 (15.6) 0.001
83 (4.6) 31 (2.4) 0.001
1,508 (86.1) 1,074 (85.2) 0.02
1,070 (61.1) 821 (65.2) 0.001
1,350 (77.1) 879 (69.8) 0.001
164 (9.4) 97 (7.7) 0.244
835 (47.7) 638 (50.6) 0.003
1,626 (92.8) 1,168 (92.7) 0.21
578 (33) 357 (28.3) 0.02
690 (39.4) 354 (28.1) 0.001
301 (17.2) 198 (15.7) 0.001
36 (2.1) 11 (0.9) 0.02
tdy Treatment
Enrollment Group
Total11–30 >30
1,792 1,289 4,133
1,106 (61.7) 882 (68.4) 2,467 (59.7)
327 (18.3) 232 (18.0) 761 (18.4)
91 (5.1) 37 (2.9) 252 (6.1)
268 (14.9) 138 (10.7) 653 (15.8)
12 (0.7) 8 (0.6) 35 (0.8)
7 (0.4) 0 (0.0) 10 (0.2)
68 (3.8) 22 (1.7) 155 (3.7)
178 (9.9) 108 (8.4) 446 (10.8)
3 (0.2) 0 (0.0) 7 (0.2)hargn and
0
79.3)
41.3)
75.1)
9.6)
39.9)
96.5)
36.9)
49.7)
22.5)
6.5)
82.3)
51.2)
77.9)
8.2)
43.5)
94.4)
31.6)
49.1)
23.3)
2.2)tmenf Stu
a
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Site Enrollment and Trial Outcomes February 5, 2013:571–91.44, 95% CI: 1.28 to 1.62) groups had worse outcomes.
This risk was not proportional over time for sites enrolling
10 participants (HR: 2.15, 95% CI: 1.83 to 2.52 during
the first 100 days; HR: 1.42, 95% CI: 1.19 to 1.69 after
100 days compared to sites with 30 enrollees). The
ssociation between enrollment and outcome was com-
arable across regions (p  0.43). Similarly, no interac-
tion was observed between the effect of the study drug
(tolvaptan) and enrollment in this analysis (p  0.13).
After adjustment for major risk factors, participants
enrolled at sites with fewer enrollees were at a higher risk for
outcome events (HR: 1.26, 95% CI: 1.08 to 1.46 for 10;
HR: 1.22, 95% CI: 1.07 to 1.38 for 11 to 30 vs. 30
participant enrolling sites).
There was a higher all-cause mortality rate among
participants enrolled at lower enrollment sites (33%, 26%,
and 21% for 10, 11 to 30, and 30 per site enrollment,
respectively, p  0.01; HR: 1.50, 95% CI: 1.27 to 1.76
for 10; HR: 1.23, 95% CI: 1.06 to 1.43 for 11 to 30
versus 30 participant enrolling sites). These differences,
however, were reduced and no longer reached the thresh-
old of statistical significance after controlling for baseline
participants differences (HR: 1.12, 95% CI: 0.92 to 1.35,
p  0.26 for 1 to 10; HR: 1.07, 95% CI: 0.91 to 1.26, p 
0.39 for 11 to 30 vs. 30 participant enrolling sites)
(Fig. 3).
Table 4 shows the distribution of other outcomes in
the 3 groups. Besides all-cause mortality and cardiovas-
cular mortality, worsening HF, and HF hospitalizations,
all other causes of hospitalizations except for those
Figure 2 Cardiovascular Mortality or Heart Failure Hospitalizati
Kaplan-Meier event curves (colored lines) with 95% point-wise confidence limits (s
at sites with lower enrollment were at higher risk for adverse events.related to acute myocardial infarction were also morelikely among participants enrolled in sites with overall
lower enrollment.
Discussion
In this analysis we demonstrate that, despite strict inclusion
and exclusion criteria for eligibility to enroll in a clinical
trial, there are significant differences in baseline clinical
characteristics among study sites according to enrollment
volume. Such variations have been previously reported
related to regional differences among participants. To our
knowledge, this is the first report that shows significant
differences in participants’ baseline clinical characteristics on
the basis of the number of participants enrolled by any
individual clinical trial site. These differences spanned de-
mographic and clinical characteristics, comorbidity burden,
and laboratory parameters. Participants from the trial sites
that enrolled fewer individuals had worse health at baseline.
The less prevalent dyspnea and rales coupled with lower
blood pressure and worse renal function, and higher use of
inotropes all suggest that participants enrolled at lower
enrolling sites likely represent a proportion of participants in
low cardiac output state as well. The higher ejection fraction
and lower proportion of participants with implanted defi-
brillators on the contrary further suggest that participants
enrolled in higher enrolling sites had less severe HF. Not
surprisingly, these differences correlated with clinical out-
comes and protocol completion rates, with participants
enrolled at sites with fewer participants being at higher risk
for adverse outcomes and less likely to complete the proto-
col. Interestingly, such differences in the outcome of car-
Overall Site Enrollment
areas) are displayed for each of the 3 enrollment groups. Participants enrolledon by
hadeddiovascular death or HF hospitalization persisted even after
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of participants enrolled by a site remained as an independent
predictor of this outcome. Therefore, factors related to trial
sites beyond the participants’ clinical characteristics that
were available and adjusted for, might also play a role in
patient outcomes. Finally, these characteristics were not
only related to clinical outcomes but also to completion of
the entire trial protocol. Early withdrawal related to both
Figure 3 All-Cause Mortality by Overall Site Enrollment
Kaplan-Meier event curves (colored lines) with 95% point-wise confidence limits (s
at sites with lower enrollment were at higher risk for all-cause mortality.
Clinical Outcome Rates Among Participants GroTable 4 Clinical Outcome Rates Among Par
Variable
Mortality and morbidity
All-cause mortality
Cardiovascular mortality/heart failure hospitalization
Cardiovascular mortality
Cardiovascular mortality/cardiovascular hospitalization
Worsening heart failure
Heart failure
Acute myocardial infarction
Sudden cardiac death
Stroke
Other cardiovascular mortality
Noncardiovascular mortality
Unknown cause
Rehospitalization
Heart failure
Myocardial infarction
Stroke
Other cardiovascular
Unscheduled visitValues are n (%). All-cause mortality figures in Table 4 represent all participan
were lost to follow-up and were subsequently found to have died; hence theadverse events and other reasons were more common among
sites that enrolled fewer participants.
Difficulties of successful clinical trial conduct are signif-
icant. In particular, recruitment and retention can be a
significant barrier to successful trial conduct. The challenges
of recruitment are complex. Clinical trials conducted within
the United States have significantly decreased over the past
decade whereas a parallel increase has been noted in the
areas) are displayed for each of the 3 enrollment groups. Participants enrolled
ased on Site Enrollment Statusnts Groups Based on Site Enrollment Status
Site Enrollment Group
p Value1–10 11–30 >30
43 (32.6) 468 (26.1) 269 (20.9) 0.001
32 (50.6) 761 (42.5) 407 (31.6) 0.001
57 (24.4) 365 (20.4) 207 (16.1) 0.001
01 (57.1) 877 (48.9) 486 (37.7) 0.001
00 (47.5) 662 (36.9) 334 (25.9) 0.001
64 (15.6) 185 (10.3) 94 (7.3) 0.001
5 (0.5) 12 (0.7) 11 (0.9) 0.54
68 (6.5) 134 (7.5) 80 (6.2) 0.33
6 (0.6) 13 (0.7) 5 (0.4) 0.48
15 (1.4) 22 (1.2) 17 (1.3) 0.90
54 (5.1) 61 (3.4) 28 (2.2) 0.001
32 (3.0) 42 (2.3) 34 (2.6) 0.53
07 (38.7) 582 (32.5) 297 (23) 0.001
19 (1.8) 30 (1.7) 18 (1.4) 0.72
17 (1.6) 39 (2.2) 13 (1.0) 0.04
99 (9.4) 154 (8.6) 89 (6.9) 0.07
34 (3.2) 36 (2.0) 5 (0.4) 0.001hadedups Bticipa
3
5
2
6
5
1
4ts who died as compared with Table 3 that only includes patients who
2 sets of numbers do not match.
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Food and Drug Administration–regulated investigators
based outside the United States has grown by 15% annually,
whereas those based in the United States has declined by
5.5% (14). One-third of the Phase 3 industry-sponsored
trials were being conducted solely outside the United States
and a majority of study sites were outside the United States
as well according to 1 estimate (15). Among 300 clinical
trial reports between 1995 and 2005, the number of coun-
tries serving as trial sites outside the United States more
than doubled in 10 years (11,16). The underlying reasons
for this are complex and include cost savings and shortening
timeline. The cost to develop a new drug averaged $802
million in 2000, with time costs accounting for half of the
amount (17). This is driven by slow recruitment in trials and
higher costs of keeping a large number of sites open.
Imbalances in enrollment across regions however, can
pose problems with participant case mix and in turn the
generalizability of results. Our data add a new dimension to
this debate that even within a region, the total number of
participant enrolled in a trial may be associated with
participant characteristics and outcomes and, in turn, the
trial’s results. Our data demonstrate that, irrespective of
region, the sites with fewer enrollees tended to enroll
participants at higher risk for worse outcomes. The corre-
lation between the higher risk on the basis of clinical
characteristics and the actual event rate is consistent, further
strengthening our results. Thus site enrollment rate in itself
may affect the generalizability of results and outcomes of the
drug being tested in the trial. These data are of significance,
if replicated, in terms of future trial design and conduct.
Though the results are straightforward, the interpretation
of our study is more complex. First, are these data reliable?
Considering the large number of participants and event rate
in the EVEREST trial, the consistency of findings across
the various domains of baseline clinical characteristics, and
the consistency between the expected relationship on the
basis of differences at randomization and the actual out-
comes; it is unlikely that these data represent chance
findings. These data need to be replicated, however, in other
cohorts, including assessing whether such a paradigm is
specific to AHF or exists with chronic HF or clinical trial
beyond HF.
A second issue is how to explain these differences in
participant characteristics between high versus low enrolling
centers. It is possible that some high enrolling centers were
lax in following the inclusion and exclusion criteria and
enrolled participants who were borderline candidates in
terms of eligibility, were less sick, and this led to higher
enrollment. On the contrary, or in addition, it is possible
that low enrolling sites included participants who were too
sick, representing a desire by participants and providers to
pursue any options available. Such participants may have
other disadvantaged social factors that predisposed them to
worse outcomes as well. Whether these reasons underlie ourresults or if there are other explanations cannot be clearly
elucidated by the current data.
Understanding the dynamics that underlie these results,
however, is important in terms of future trial design.
Assuming that these results are replicated, should we
recommend a shift in the direction of sites that enroll more
or fewer participants? Are participants from low enrollment
centers too sick to benefit regardless of the therapy, or are
participant from high enrollment centers not likely to
benefit as a certain proportion of them have low baseline
risk implying a narrow therapeutic window for benefit.
These are important issues to contend with because they
may determine the fate of the trial beyond the intrinsic
capacities of the drug or device under investigation.
Another important facet of our data is how to explain the
independent influence of the sites that enrolled higher
versus lower participants on outcomes even after the base-
line participant characteristics were accounted for. Again,
many hypotheses can be proposed but cannot be proven by
the current data. Did centers that enrolled fewer partici-
pants more frequently enroll socioeconomically disadvan-
taged populations? Did they have fewer staff or less sophis-
ticated infrastructures for research and, by extension, for
clinical care? Were less frequent appropriate therapies in
general for participants in lower enrollment centers a func-
tion of quality of care or related to participant severity of
illness? Another important issue is the financial incentive
structure to the investigators at sites and regions that had
more robust enrollment than those that did not. It is
possible that direct or indirect financial incentives to the
investigators versus to the institutions may play a role in the
overall enrollment and the kind of participants that are
enrolled in a trial. Furthermore, when a study is slow in
enrolling, the current standard default is for new sites to be
added, instead of providing more finances and nonfinancial
support to the existing sites. These are important issues to
understand in order to explain our findings, but nevertheless
underscore the importance of careful site selection for
clinical trials.
Study limitations. We did not have the data on site
initiation dates. Similarly for sites that did not participate in
the trial until its closure, we do not have the date for the site
termination. In the absence of these dates, we analyzed the
data on the basis of overall enrollment per site as opposed to
the rate of enrollment over a given unit period of time. Also,
although our data show variation in outcomes by site
enrollment status, we do not have granular data for the
participants’ nonmedical determinant of health outcomes,
or for the site structure and processes, to further explain our
findings. Despite covariate adjustment, other measured and
unmeasured factors may have influenced these findings.
One of the most important limitations is that most of the
data regarding site characteristics such as practice setting
(academic vs. nonacademic, teaching vs. nonteaching, avail-
ability of advanced services); location (rural vs. urban);
hospital and practice size; physician, nursing, and research
11
1
1
1
2
2
2
2
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were not available. Thus further explaining these results on
the basis of site-specific characteristics is not possible. It is
rare that these data are routinely presented in results or
taken into consideration when interpreting clinical trials
data. This raises another important issue that the absence of
these data might indicate that site selection and trials
conduct are performed without detailed knowledge of site-
specific characteristics. Our results underline the importance
of uniformly collecting more data regarding site character-
istics when conducting future clinical trials.
Conclusions
Recent problems with recruitment in clinical trial in the
United States and Western Europe are well known (11).
Variation in participant characteristics and outcomes among
the various regions of the world has been documented
(7–10,18). Regional differences in outcomes may be ex-
plained on the basis of differences in quality of care and the
social and genetic makeup of study populations (19–23).
We add a new dimension to the complexities of conducting
clinical trials, namely that overall enrollment per site is
associated with participant characteristics, protocol comple-
tion, and outcomes. This raises the hypothesis that for novel
drug or device therapy, outcomes can be affected by site
performance and characteristics, and that these factors
should be taken under consideration when designing AHF
trials.
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